Exagen (XGN) EBIAT (2018 - 2025)
Historic EBIAT for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.
- Exagen's EBIAT fell 4095.07% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1247.71%. This contributed to the annual value of -$15.1 million for FY2024, which is 3619.4% up from last year.
- According to the latest figures from Q3 2025, Exagen's EBIAT is -$7.1 million, which was down 4095.07% from -$4.4 million recorded in Q2 2025.
- Exagen's EBIAT's 5-year high stood at -$3.0 million during Q2 2024, with a 5-year trough of -$14.7 million in Q2 2022.
- Its 5-year average for EBIAT is -$6.8 million, with a median of -$6.2 million in 2021.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 12878.32% in 2022, then skyrocketed by 6581.66% in 2023.
- Over the past 5 years, Exagen's EBIAT (Quarter) stood at -$7.1 million in 2021, then plummeted by 103.52% to -$14.4 million in 2022, then surged by 61.17% to -$5.6 million in 2023, then surged by 32.51% to -$3.8 million in 2024, then plummeted by 88.43% to -$7.1 million in 2025.
- Its last three reported values are -$7.1 million in Q3 2025, -$4.4 million for Q2 2025, and -$3.8 million during Q1 2025.